RT Journal Article
T1 Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population.
A1 López-Cortés, Luis F
A1 Viciana, Pompeyo
A1 Girón-González, José A
A1 Romero-Palacios, Alberto
A1 Márquez-Solero, Manuel
A1 Martinez-Perez, Maria A
A1 López-Ruz, Miguel A
A1 Torre-Lima, Javier de la
A1 Téllez-Pérez, Francisco
A1 Delgado-Fernández, Marcial
A1 Garcia-Lázaro, Milagros
A1 Lozano, Fernando
A1 Mohamed-Balghata, Mohamed O
K1  Reverse Transcriptase Inhibitors
K1  Nevirapine
K1  Protease Inhibitors
K1  Viral Load
K1  Intention to Treat Analysis
K1  Antiviral Agents
K1  Treatment Outcome
K1  HIV Infections
K1 AGS Campo de Gibraltar Oeste
K1 AGS Sur de Sevilla
AB Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs). This multicenter study aimed to assess the efficacy of this combination in two scenarios: group A) subjects without virologic failure on or no experience with non-nucleoside reverse-transcriptase inhibitors (NNRTIs) switched due to adverse events and group B) subjects switched after a virologic failure on an efavirenz- or nevirapine-based regimen. The primary endpoint was efficacy at 52 weeks analysed by intention-to-treat. Virologic failure was defined as the inability to suppress plasma HIV-RNA to <50 copies/mL after 24 weeks on treatment, or a confirmed viral load >200 copies/mL in patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Two hundred eighty seven patients were included. Treatment efficacy rates in group A and B were 88.0% (CI95, 83.9-92.1%) and 77.4% (CI95, 65.0-89.7%), respectively; the rates reached 97.2% (CI95, 95.1-99.3%) and 90.5% (CI95, 81.7-99.3), by on-treatment analysis. The once-a-day ETV treatment was as effective as the twice daily dosing regimen. Grade 1-2 adverse events were observed motivating a treatment switch in 4.2% of the subjects. In conclusion, ETV (once- or twice daily) plus two analogs is a suitable, well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug activity.
PB Public Library of Science
YR 2014
FD 2014-05-16
LK http://hdl.handle.net/10668/1629
UL http://hdl.handle.net/10668/1629
LA en
NO López-Cortés LF, Viciana P, Girón-González JA, Romero-Palacios A, Márquez-Solero M, Martinez-Perez MA, et al. Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population. PLoS ONE. 2014; 9(5):e97262
NO Journal Article; ClinicalTrials.gov NCT01437241.
DS RISalud
RD Jul 7, 2025